Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,851-1,900 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__88_A8,9 | Lung | Primary cancer | 2,808 | Tumor/Malignant | 76.3% | 0.95 | 0.14 |
| NSCLC_38242124__IMC__88_B1,1 | Lung | Primary cancer | 4,170 | Tumor/Malignant | 49.8% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__88_B1,10 | Lung | Primary cancer | 3,178 | Tumor/Malignant | 63.2% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__88_B1,11 | Lung | Primary cancer | 8,194 | Immune | 48.0% | 0.79 | 0.44 |
| NSCLC_38242124__IMC__88_B1,12 | Lung | Primary cancer | 2,767 | Tumor/Malignant | 64.5% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__88_B1,14 | Lung | Primary cancer | 3,280 | Tumor/Malignant | 38.0% | 0.76 | 0.53 |
| NSCLC_38242124__IMC__88_B1,15 | Lung | Primary cancer | 2,914 | Stromal | 40.2% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__88_B1,16 | Lung | Primary cancer | 2,650 | Tumor/Malignant | 78.5% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__88_B1,2 | Lung | Primary cancer | 3,987 | Tumor/Malignant | 66.4% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__88_B1,3 | Lung | Primary cancer | 4,072 | Immune | 33.0% | 0.45 | 0.86 |
| NSCLC_38242124__IMC__88_B1,4 | Lung | Primary cancer | 2,870 | Tumor/Malignant | 74.4% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__88_B1,5 | Lung | Primary cancer | 3,425 | Tumor/Malignant | 46.5% | 0.74 | 0.53 |
| NSCLC_38242124__IMC__88_B1,6 | Lung | Primary cancer | 3,172 | Tumor/Malignant | 62.9% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__88_B1,7 | Lung | Primary cancer | 3,614 | Tumor/Malignant | 79.8% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__88_B1,8 | Lung | Primary cancer | 3,530 | Tumor/Malignant | 37.3% | 0.95 | 0.18 |
| NSCLC_38242124__IMC__88_B1,9 | Lung | Primary cancer | 3,597 | Immune | 33.8% | 0.43 | 0.90 |
| NSCLC_38242124__IMC__88_B2,10 | Lung | Primary cancer | 2,913 | Tumor/Malignant | 52.9% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__88_B2,11 | Lung | Primary cancer | 2,095 | Tumor/Malignant | 29.1% | 0.59 | 0.86 |
| NSCLC_38242124__IMC__88_B2,12 | Lung | Primary cancer | 3,199 | Tumor/Malignant | 58.4% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__88_B2,13 | Lung | Primary cancer | 2,837 | Tumor/Malignant | 76.4% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__88_B2,14 | Lung | Primary cancer | 3,699 | Tumor/Malignant | 42.8% | 0.94 | 0.20 |
| NSCLC_38242124__IMC__88_B2,15 | Lung | Primary cancer | 2,967 | Tumor/Malignant | 53.5% | 0.93 | 0.19 |
| NSCLC_38242124__IMC__88_B2,16 | Lung | Primary cancer | 2,965 | Stromal | 42.5% | 0.95 | 0.17 |
| NSCLC_38242124__IMC__88_B2,2 | Lung | Primary cancer | 3,574 | Tumor/Malignant | 55.7% | 0.89 | 0.29 |
| NSCLC_38242124__IMC__88_B2,3 | Lung | Primary cancer | 5,348 | Tumor/Malignant | 62.2% | 0.94 | 0.17 |
| NSCLC_38242124__IMC__88_B2,4 | Lung | Primary cancer | 3,042 | Tumor/Malignant | 51.6% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__88_B2,5 | Lung | Primary cancer | 4,928 | Tumor/Malignant | 32.2% | 0.89 | 0.36 |
| NSCLC_38242124__IMC__88_B2,6 | Lung | Primary cancer | 3,667 | Tumor/Malignant | 71.1% | 0.94 | 0.17 |
| NSCLC_38242124__IMC__88_B2,7 | Lung | Primary cancer | 3,297 | Tumor/Malignant | 41.4% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__88_B2,9 | Lung | Primary cancer | 2,533 | Immune | 26.9% | 0.60 | 0.76 |
| NSCLC_38242124__IMC__88_B3,1 | Lung | Primary cancer | 3,047 | Other | 28.4% | 0.42 | 0.93 |
| NSCLC_38242124__IMC__88_B3,10 | Lung | Primary cancer | 1,646 | Stromal | 41.4% | 0.76 | 0.54 |
| NSCLC_38242124__IMC__88_B3,11 | Lung | Primary cancer | 396 | Tumor/Malignant | 79.5% | 0.96 | 0.11 |
| NSCLC_38242124__IMC__88_B3,12 | Lung | Primary cancer | 2,461 | Tumor/Malignant | 62.6% | 0.98 | 0.12 |
| NSCLC_38242124__IMC__88_B3,13 | Lung | Primary cancer | 2,525 | Tumor/Malignant | 63.0% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__88_B3,14 | Lung | Primary cancer | 2,309 | Tumor/Malignant | 47.4% | 0.96 | 0.18 |
| NSCLC_38242124__IMC__88_B3,15 | Lung | Primary cancer | 3,583 | Tumor/Malignant | 60.0% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__88_B3,16 | Lung | Primary cancer | 2,973 | Tumor/Malignant | 55.3% | 0.92 | 0.24 |
| NSCLC_38242124__IMC__88_B3,4 | Lung | Primary cancer | 5,405 | Stromal | 57.5% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__88_B3,5 | Lung | Primary cancer | 3,434 | Tumor/Malignant | 55.5% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__88_B3,6 | Lung | Primary cancer | 4,461 | Tumor/Malignant | 42.0% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__88_B3,7 | Lung | Primary cancer | 3,167 | Stromal | 37.3% | 0.76 | 0.51 |
| NSCLC_38242124__IMC__88_B3,8 | Lung | Primary cancer | 2,624 | Tumor/Malignant | 28.4% | 0.90 | 0.32 |
| NSCLC_38242124__IMC__88_B3,9 | Lung | Primary cancer | 2,779 | Tumor/Malignant | 35.9% | 1.00 | 0.06 |
| NSCLC_38242124__IMC__88_B4,1 | Lung | Primary cancer | 1,954 | Tumor/Malignant | 63.8% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__88_B4,10 | Lung | Primary cancer | 2,510 | Tumor/Malignant | 43.6% | 0.96 | 0.16 |
| NSCLC_38242124__IMC__88_B4,11 | Lung | Primary cancer | 2,674 | Tumor/Malignant | 75.1% | 0.95 | 0.13 |
| NSCLC_38242124__IMC__88_B4,12 | Lung | Primary cancer | 2,865 | Tumor/Malignant | 43.5% | 0.94 | 0.21 |
| NSCLC_38242124__IMC__88_B4,14 | Lung | Primary cancer | 2,759 | Immune | 23.8% | 0.84 | 0.43 |
| NSCLC_38242124__IMC__88_B4,15 | Lung | Primary cancer | 4,974 | Tumor/Malignant | 80.4% | 0.98 | 0.08 |